Association of CYP24A1 with survival and drug resistance in clinical cancer patients: a meta-analysis

BMC Cancer

Table 1 Main Characteristics and quality assessment of included 15 studies

Author	Year	Cancer type	ethnicities	CYP24A1 detection	CYP24A1 type	Sample size	CYP24A1^high/SNP	CYP24A1^low/WT	Treat ment	Outcome	NOS scale
Chen G ^[[[[30]]]]	2011	LC	unknown	protein	expr	101	35	66	No	OS	8
Ge N [41]	2017	LC	China	protein	expr	64	31	33	No	OS	8
Sun H [31]	2016	CRC	unknown	protein	expr	99	69	30	No	OS, DFS	8
Porter, R. L [42]	2019	LC	unknown	protein	expr	497	13	485	Chemo	OS	7
Kong, J [33]	2015	LC	China	mRNA	expr	153	na	na	No	OS	8
Borkowski, R [43]	2015	LC	North America	mRNA	expr	182	na	na	No	OS, RFS	8
Mimori, K [44]	2004	EC	Japan	mRNA	expr	42	17	25	No	OS	8
Cai, H [45]	2019	BC	North America	mRNA	expr	1102	646	456	No	OS, RFS	8
Deng, Y. B [46]	2010	HC	unknown	methylation	expr	57	35	22	No	DFS	7
Ramnath, N [47]	2014	LC	unknown	methylation	expr	68	22	46	Chemo	OS, DFS	7
Azad, A. K [48]	2013	HNC	unknown	rs2296241	SNP	522	na	na	Chemo	OS	8
Lancheros, L [49]	2021	LC	Southern Spain	rs6068816	SNP	179	na	na	Chemo	OS, PFS	8
Hlaváč, V [50]	2021	BC	unknown	rs2762934	SNP	369	122	247	Chemo	DFS	8
Gong, C [51]	2017	CRC	northeast China	rs4809957	SNP	264	58	206	No	OS	8
Vidigal, V. M [52]	2017	CRC	unknown	rs6013897	SNP	85	17	68	No	OS	8

Notes: CRC Colorectal cancer, LC Lung cancer, EC Esophageal cancer, BC Breast cancer, HC Hepatocellular carcinoma, HNC Head and neck cancer, expr Expression, Chemo Chemo-drugs, OS Overall survival, RFS Relapse free survival, DFS Disease free survival

ISSN: 1471-2407